HbA1c, Waist-to-Height Ratio Predict Dyslipidemia in T1DM

Share this content:
HbA1c, Waist-to-Height Ratio Predict Dyslipidemia in T1DM
HbA1c, Waist-to-Height Ratio Predict Dyslipidemia in T1DM

WEDNESDAY, Feb. 1, 2017 (HealthDay News) -- For youth with type 1 diabetes, hemoglobin A1c (A1C) and waist-to-height ratio (WHtR) are modifiable risk factors that predict change in dyslipidemia, according to a study published online Jan. 26 in Diabetes Care.

Amy S. Shah, M.D., from Cincinnati Children's Hospital & University of Cincinnati, and colleagues examined the risk factors associated with progression and regression of dyslipidemia in 1,478 youths with type 1 diabetes at baseline and at a mean follow-up of 7.1 years.

The researchers found that 19, 5, 69, and 7 percent of youth with type 1 diabetes had non-high-density lipoprotein cholesterol (HDL-C) that progressed, regressed, was stable normal, and stable abnormal, respectively. For HDL-C, the corresponding percentages were 3, 3, 94, and 1 percent. Higher A1C area under the curve (AUC) and higher WHtR AUC in males were associated with non-HDL-C progression. Lower WHtR AUC was associated with non-HDL-regression, while male sex and higher WHtR AUC correlated with HDL-C progression. Due to small numbers, HDL-C regression was not modeled.

"A1C and WHtR are modifiable risk factors associated with change in dyslipidemia over time in youth with type 1 diabetes," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »